Metastasis, involving the spread of systemic cancer to the brain, results in neurologic
disability and death. Current treatments are largely palliative in nature; improved therapeutic …

Leptomeningeal metastasis is an uncommon and typically late complication of cancer with a
poor prognosis and limited treatment options. Diagnosis is often challenging, with …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

PURPOSE In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …

These EANO–ESMO joint recommendations for the diagnosis and treatment of
leptomeningeal metastasis (LM) from solid cancers represent the first European guideline …

PURPOSE Photon involved-field radiotherapy (IFRT) is the standard-of-care radiotherapy for
patients with leptomeningeal metastasis (LM) from solid tumors. We tested whether proton …

Leptomeningeal metastasis is a complication of advanced non-small-cell lung cancer
(NSCLC). Diagnosis and monitoring of leptomeningeal metastasis are challenging, and are …

Introduction Leptomeningeal metastases (LM) have increased in patients with NSCLC, and
prognostic factors and outcomes for LM with EGFR gene mutations have not been well …

Leptomeningeal metastasis (LM) results from metastatic spread of cancer to the
leptomeninges, giving rise to central nervous system dysfunction. Breast cancer, lung …

Leptomeningeal disease has become increasingly prevalent as novel therapeutic
interventions extend the survival of cancer patients. Although a majority of leptomeningeal …